Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: Rational design for Osteotropic Drug Delivery System (ODDS)

Pharmaceutical Research

Volumn 18, Issue 5, 2001, Pages 646-651

  Hirabayashi, Hideki ^a   Sawamoto, Taiji ^a   Fujisaki, Jiro ^a   Tokunaga, Yuji ^a   Kimura, Sumihisa ^a   Hata, Takehisa ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Bisphosphonate; Distribution volume; Lipophilicity; Osteotropic drug delivery system; Plasma clearance; Solubility

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM DERIVATIVE; DICLOFENAC;

ARTICLE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG SOLUBILITY; HYDROPHILICITY; LIPOPHILICITY; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT;

ALGORITHMS; ANIMALS; BONE AND BONES; CHEMISTRY, PHYSICAL; DIPHOSPHONATES; LIPIDS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPLEEN;

EID: 0034950244     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011033326980     Document Type: Article

References (30)

1. Theory and practice of site-specific drug delivery
2. Chemical delivery systems
3. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: Synthesis and in vivo characterization of osteotropic carboxyfluorescein
4. Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery
5. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: Pharmacokinetics and targeting characteristics of osteotropic Carboxyfluorescein
6. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. IV: Effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats
7. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. V: Biological disposition and targeting characteristics of osteotropic estradiol
8. Bone specific delivery and sustained release of diclofenac, a non-steroidal antiinflammatory drug, via bisphosphonic prodrug based on osteotropic drug delivery system (ODDS)
9. Treatment of Paget's disease of bone
10. The treatment of hypercalcaemia of malignancy
11. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment
12. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
13. Structure-activity relationships (SAR) of hydroxyapatite-binding molecules
14. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives
15. The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro
16. Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice
17. A pharmacokinetic analysis program (MULTI) for microcomputer
18. Physiologically based pharmacokinetic modeling: Principles and applications
19. Plasma protein binding of APD: Role of calcium and transferrin
20. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats
21. Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats
22. Development of quantitative structure-activity relationships and computer-aided drug design
23. Strategies and recent technologies in drug discovery
24. Computational ligand design
25. Development of quantitative structure-pharmacokinetic relationships
26. Quantitative structurepharmacokinetic relationships (QSPR) of beta blockers derived using neural networks
27. Structure-activity relationships of various bisphosphonates
28. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group
29. Clinical experience with aminohydoxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia
30. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydoxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia